| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4250996 | Seminars in Nuclear Medicine | 2012 | 8 Pages |
Abstract
18F-Fluorodeoxyglucose avidity for gastroenteropancreatic neuroendocrine tumors and hepatocellular carcinoma is variable, depending on the underlying tumor biology. Experience with non-fluorodeoxyglucose (FDG) tracers (eg, 18F-labeled amine precursors l-dihydroxyphenylalanine and 68Ga-DOTA-peptides for gastroenteropancreatic neuroendocrine tumors and radiolabeled acetate or choline for hepatocellular carcinoma) is evolving and expanding rapidly. This article reviews the role of FDG and non-FDG radiotracers in the imaging evaluation of patients with gastroenteropancreatic neuroendocrine tumors or hepatocellular carcinoma.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Hossein MD, PhD, MPH, MBA,